|
Over the seventeen years since NI Research began publishing NeuroPerspective (formerly NeuroInvestment), and as we have added our annual reviews of the CNS licensing and Private CNS Company areas, NI Research has acquired a unique knowledge-base and perspective on the neurotherapeutics industry. Increasingly, companies are utilizing our expertise as they consider their own strategic plans and alternatives. NI Research offers consultation regarding strategic planning and licensing and alliance opportunities within the neurotherapeutics area. We do not offer competitive intelligence services.
|
|
Recent consultation projects have included:
- Collaborated with a multinational major pharmaceutical company on a strategic review of their CNS platform and opportunities--including licensing and M&A. The project included coordination with R&D, Business Development, and Commercial staff members.
- Strategic planning for a small CNS company which had recently outlicensed its lead program, and was seeking input regarding the optimal path forward: inlicensing, internal development, or M&A.
- Provided review and recommendations regarding clinical-stage inlicensing options for a 'development only' CNS specialty company.
- Assisted a major biotech information firm with identifying the most promising CNS licensing opportunities for a conference devoted to alliance and partnership building.
- Worked with a private CNS company in delineating a hierarchy of priorities for their inhouse programs and inlicensing opportunities.
- Provided consultation to a private company assessing licensing options for its lead clinical program.
|
